Received Aug 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 9L5P2 | — |
A male patient received Shingrix in 2020 and the second dose in 2024, now he wants a 3rd dose.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 59-year-old male patient who received Herpes zoster (Shingrix) (batch number 9L5P2, expiry date 27-OCT-2026) for prophylaxis. Previously administered products included Shingrix (1st dose received on 08-DEC-2020, batch number-4Z43X and expiration date 22-FEB-2022). On 11-NOV-2024, the patient received the 2nd dose of Shingrix. On 11-NOV-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: A male patient received Shingrix in 2020 and the second dose in 2024, now he wants a 3rd dose.). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 11-AUG-2025 The patient received second dose of Shingrix at longer interval than recommended which led to lengthening of vaccination schedule. At the time of reporting the patient wants a 3rd dose. The reporter asked was this possible, what would be the dosing schedule or the safety information. The reporter consented to follow up.